Form 4: Tyra Biosciences VP Finance Acquires Stock Options

Yuliya Rueb, Vice President of Finance at Tyra Biosciences, acquired stock options and restricted stock units.

Summary

• Yuliya Rueb, Vice President of Finance at Tyra Biosciences, Inc., acquired 8,333 restricted stock units (RSUs) and 28,000 stock options on May 5, 2026.
• The RSUs vest over four years, with 1/4 vesting annually on the anniversary of the grant date, subject to continued service.
• The stock options have an exercise price of $33.93 and vest over 48 months, with 1/48th vesting monthly following the grant date, also subject to continued service.
• Following these transactions, Rueb beneficially owns 43,354 shares of common stock, including the RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details standard executive compensation and does not provide new financial performance data or strategic shifts.

Positives

• Grant of stock options and RSUs to a key executive (VP of Finance) indicates management's commitment and potential for future growth.
• The vesting schedules for both RSUs and stock options are tied to continued service, aligning executive incentives with long-term company performance.
• The exercise price of the stock options ($33.93) suggests a current market valuation that the company believes can be surpassed.

Negatives

• The filing does not provide specific financial performance data, making it difficult to assess the immediate impact on the company's financial health.
• The acquisition of options and RSUs is a standard compensation practice and does not inherently represent a positive financial event for the company itself, but rather for the executive.

Risks

• The value of the stock options and RSUs is directly tied to the future performance of Tyra Biosciences' stock price, which is subject to market volatility and company-specific risks.
• Vesting is contingent on continued employment, meaning a departure of the executive before vesting could result in forfeiture of these awards.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term outlook for the company, as the executive's incentives are tied to continued service and stock performance over several years.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to finance executives is a common practice in the biotechnology sector to attract and retain talent, especially in growth-oriented companies. This aligns with industry standards for executive compensation.

Stakeholder Impact

• Shareholders: The grant of equity awards to management is a standard compensation practice. The ultimate impact on shareholders depends on the company's future performance and stock price appreciation.
• Employees: This filing may signal a stable management structure and continued investment in key personnel, potentially boosting employee morale.
• Management: Yuliya Rueb benefits from potential future gains on her stock options and RSUs, contingent on company performance and continued employment.

Next Steps

• Continued service by Yuliya Rueb through the vesting dates of the RSUs and stock options.
• Monitoring of Tyra Biosciences' stock performance to determine the value realization of the granted equity awards.

Key Dates

Keywords

Tyra Biosciences, Form 4, Stock Options, Restricted Stock Units, Insider Trading, Executive Compensation, SEC Filing, Yuliya Rueb, Vice President Finance